A

Rating buyAI Memo

Agilent

As of 2026-09-08/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

6‑12m

Key catalyst

Q3 FY2026 beat and raised outlook • 2026-08-26

Base target: $176 / p=55% prob

Biggest risk

The raised outlook still requires sustained demand and execution, while the Q3 result benefited from tariff refunds and the Biocare catalyst remains subject to closing and integration risk. No post-print analyst revision set is available.

Invalidation

Break below $135 or thesis failure.

What would change my mind?

The Q3 beat, strong core growth, improving end markets, operational leverage, product launches, and raised FY2026 outlook support continued earnings momentum [#SEC-8K-2026-08-26].

Research note

Recommendation

buy

Confidence

high

As of

2026-09-08

Base target

$176

p=55%

Bull target

$195

p=25%

Bear target

$135

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

One-time tariff benefit creates comparison risk
Biocare acquisition and pathology expansion
The Q3 beat, strong core growth, improving end markets, operational leverage, product launches, and raised FY2026 outlook support continued earnings momentum [#SEC-8K-2026-08-26].

BearKey bullets

Analyst target count, post-earnings estimate revisions, and options positioning are unavailable.
Biocare closing and integration timing remain execution variables [#PR-2026-03-09].
Q3 EPS and margin benefited from tariff refunds that are not assumed in fourth-quarter guidance [#SEC-8K-2026-08-26].

WatchKey bullets

Q3 FY2026 beat and raised outlook

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $176 (p=55%)

Target spread vs base: +11% / -23%

Scenario probabilities

Bull Target: $195 (p=25%)Base Target: $176 (p=55%)Bear Target: $135 (p=20%)

Commentary

News tone is constructive after the Q3 beat and raised FY2026 outlook, but the packet lacks a verified post-print analyst revision set, options data, and social coverage. The stock remains a positive but monitoring-oriented setup because part of the earnings upside came from tariff refunds [#SEC-8K-2026-08-26].

As of 2026-09-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

The Q3 beat, strong core growth, improving end markets, operational leverage, product launches, and raised FY2026 outlook support continued earnings momentum [#SEC-8K-2026-08-26].

Bear Case

Drivers

Scannable catalysts and supporting factors

One-time tariff benefit creates comparison risk
Biocare acquisition and pathology expansion

Scenarios

Bull Target (Scenario probability)

$195 / p=25% prob

Base Target (Scenario probability)

$176 / p=55% prob

Bear Target (Scenario probability)

$135 / p=20% prob

Analysis 2026-09-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-26
Q3 FY2026 beat and raised outlook
Agilent reported $1.88 billion of revenue, 7.3% core growth, non-GAAP EPS of $1.62, and raised FY2026 revenue, margin, and EPS guidance. The result exceeded the high end of prior EPS guidance by $0.06 before tariff refunds [#SEC-8K-2026-08-26].
Prob 90.00% • Move 6.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

One-time tariff benefit creates comparison risk
2026-10-31
Q3 non-GAAP EPS included a $0.06 tariff-refund benefit, while fourth-quarter guidance excludes future tariff refunds. Execution must sustain the raised outlook without repeating that benefit [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].
Prob 70% • Move -4% • Priced-in 55%

Long-term Catalysts

Months to a year

Biocare acquisition and pathology expansion
2026-10-31
The previously announced Biocare Medical acquisition is targeted to close by fiscal Q4 2026 and could improve pathology exposure, mix, and growth if approvals and integration remain on schedule [#PR-2026-03-09].
Prob 65% • Move 5% • Priced-in 45%

Risks

Analyst target count, post-earnings estimate revisions, and options positioning are unavailable.
Biocare closing and integration timing remain execution variables [#PR-2026-03-09].
Q3 EPS and margin benefited from tariff refunds that are not assumed in fourth-quarter guidance [#SEC-8K-2026-08-26].
The raised FY2026 outlook depends on continued end-market improvement, demand strength, and operational execution [#SEC-8K-2026-08-26].

Peers

Symbol	Summary
WAT	Direct analytical-instruments and lab-workflow comparator for replacement-cycle and service-attachment checks; identified by Agilent as a principal competitor [#10-K-2025-12-22].
TMO	Large life-science tools and services benchmark for end-market demand and mix, though less pure-play than Agilent [#10-K-2025-12-22].
DHR	Broad diagnostics and instruments benchmark relevant to pathology and service-workflow execution [#10-K-2025-12-22].
BRKR	Focused analytical-instruments peer useful for testing whether replacement-cycle demand is broad-based or Agilent-specific [#10-K-2025-12-22].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-08

Loading AI feed…

Symbol

Summary

WAT

Direct analytical-instruments and lab-workflow comparator for replacement-cycle and service-attachment checks; identified by Agilent as a principal competitor [#10-K-2025-12-22].

TMO

Large life-science tools and services benchmark for end-market demand and mix, though less pure-play than Agilent [#10-K-2025-12-22].

DHR

Broad diagnostics and instruments benchmark relevant to pathology and service-workflow execution [#10-K-2025-12-22].

BRKR

Focused analytical-instruments peer useful for testing whether replacement-cycle demand is broad-based or Agilent-specific [#10-K-2025-12-22].